| Literature DB >> 28729908 |
Yuichiro Toda1, Kentaro Sugimoto2.
Abstract
BACKGROUND: Acute kidney injury (AKI) after cardiac surgery in children with congenital heart disease is a common complication. AKI is also associated with high morbidity and mortality. The Kidney Diseases Improving Global Outcomes (KDIGO) criteria for AKI classification are now widely used for the definition of AKI. It is noteworthy that a statement about children was added to the criteria. Many studies aimed at finding useful biomarkers are now being performed by using these criteria. Clinicians should be aware of the recent progress in understanding AKI in children. MAIN CONTENTS: Unlike adult patients, young age is one of the major risk factors for AKI in pediatric cardiac surgery. The mechanism of the development of AKI in children might be different from that in adults because the surgical procedure and CPB technique in pediatric patients are greatly different from those in adult patients. There are many biomarkers for early detection of AKI, and some of them are widely used in hospitals. One of the major benefits of such biomarkers is the rapidness of expression for detecting increases in their expression levels. Neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C, and albumin have been investigated in some studies, and the usefulness of these biomarkers for detection of AKI and diagnosis of disease severity has been shown. Although there are many interventions for preventing and treating AKI after cardiac surgery in children, there is still no specific effective treatment. Peritoneal dialysis is effective for only maintaining a negative fluid balance early after cardiac surgery. The long-term prognosis of AKI is an issue of interest. Although mortality and morbidity of AKI in the acute phase of disease remain high, the long-term condition in pediatric patients is relatively acceptable unlike in adults.Entities:
Keywords: Acute kidney injury; Biomarker; Cardiac surgery; Cardiopulmonary bypass; Children; NGAL; Urinary albumin
Year: 2017 PMID: 28729908 PMCID: PMC5517801 DOI: 10.1186/s40560-017-0242-z
Source DB: PubMed Journal: J Intensive Care ISSN: 2052-0492
Staging of AKI (KDIGO)
| Stage | Serum creatinine | Urine output |
|---|---|---|
| 1 | 1.5–1.9 times baseline or ≥0.3 mg/dl (≥26.5 μmol/l) increase | <0.5 ml/kg/h for 6–12 h |
| 2 | 2.0–2.9 times baseline | <0.5 ml/kg/h for ≥12 h |
| 3 | 3.0 times baseline or increase in serum creatinine to ≥4.0 mg/dl (≥353.6 μmol/l) or initiation of renal replacement therapy or in patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m2 | <0.3 ml/kg/h for ≥24 h or anuria for ≥12 h |
Reference [12]
Incidence of AKI and risk factors
| Author, year |
| Population, data source | Age (median or mean) | criteria | Incidence (%) | Risk factors |
|---|---|---|---|---|---|---|
| Hazle 2013 [ | 49 | Single-center, prospective biomarker study | 2 months | KDIGO | 86 | NA |
| Lex 2014 [ | 1489 | Single-center, prospective study | 1 year | KDIGO | 29 | NA |
| Meersch 2014 [ | 51 | Single-center, prospective biomarker study | 2 years | pRIFLE | 24 | NA |
| Gil-Ruiz Gil-Esparza 2014 [ | 409 | Single-center, retrospective study | 12 months | pRIFLE | 26.2 | Age, duration CPB, RACHS |
| Ruf 2015 [ | 59 | Single-center, prospective spectroscopy study | 2 months | pRIFLE | 48 | Age, univentricular anatomy |
| Sugimoto 2016 [ | 376 | Single-center, prospective biomarker study | 18 months | pRIFLE | 64.6 | Age, duration CPB |
| Park 2017 [ | 220 | Single-center, retrospective study | 6 months | KDIGO | 41.8 | Age, hemoglobin |
Fig. 1Comparison of urinary albumin in each pRIFLE category. Urinary albumin corrected by urinary creatinine. The graph shows a step-by-step increase in urinary albumin by the pRIFLE criteria. Categories in pRIFLE criteria: N normal, R risk, I injury, and F failure. Reference [15]